INNOVATION PHARMACEUTICALS INC. Debt Instrument, Convertible, Beneficial Conversion Feature
INNOVATION PHARMACEUTICALS INC. reported Debt Instrument, Convertible, Beneficial Conversion Feature of $0 for the 12-month period ending 2020-06-30, per its 10-K filed 2020-09-14.
Discontinued › Notes › Debt Instruments
us-gaap:DebtInstrumentConvertibleBeneficialConversionFeature · last filed 2020-09-14
- INNOVATION PHARMACEUTICALS INC. debt instrument, convertible, beneficial conversion feature for the quarter ending 2019-06-30 was $0.00.
- INNOVATION PHARMACEUTICALS INC. debt instrument, convertible, beneficial conversion feature for fiscal 2020 was $0.00, a 100.00% decline from fiscal 2019.
- INNOVATION PHARMACEUTICALS INC. debt instrument, convertible, beneficial conversion feature for fiscal 2019 was $1.92M.
| Period end | Debt Instrument, Convertible, Beneficial Conversion Feature 3 month | Debt Instrument, Convertible, Beneficial Conversion Feature 9 month | Debt Instrument, Convertible, Beneficial Conversion Feature 12 month |
|---|---|---|---|
| 2020-06-30 | $0.00 10-K · filed 2020-09-14 | ||
| 2019-06-30 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2020-09-14 | $1.92M 10-K · filed 2020-09-14 | |
| 2019-03-31 | $1.92M 10-Q · filed 2020-05-14 |